1xbet 로그인., Ltd.
H. Lundbeck A/S

Rxulti^®(brexpiprazole) has been approved for 1xbet 로그인 treatment of schizophrenia in adults.

1xbet 로그인., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announce that the European Commission has approved Rxulti^®(brexpiprazole) for 1xbet 로그인 treatment of schizophrenia in adults. 1xbet 로그인 approval follows 1xbet 로그인 positive opinion issued by 1xbet 로그인 Committee for Medicinal Products for Human Use (CHMP) on May 31, 2018.

Lundbeck and 1xbet 로그인 will now work with local pricing and reimbursement bodies in countries throughout Europe to help ensure that eligible patients are able to access Rxulti^®. 1xbet 로그인 medicine is expected to be made available in 1xbet 로그인 first EU markets during first half of 2019.

Brexpiprazole is a once-daily, second-generation (atypical) oral antipsychotic; it provides a combination of partial agonist activity at serotonin 5-HT_1Aand dopamine D₂receptors, and antagonist activity at serotonin 5-HT_2Areceptors. Brexpiprazole exhibits high affinity for 1xbet 로그인se receptors as well as for noradrenaline alpha_1B/2Creceptors. Brexpiprazole was discovered by 1xbet 로그인 is being co-developed by 1xbet 로그인 Lundbeck.